|
Jul 18
|
Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth
|
|
Jul 14
|
UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jun 12
|
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
|
|
Jun 12
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
|
|
Jun 11
|
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
|
|
Oct 8
|
Biotech UCB Mimics Obesity Drug Stocks With Skin Disease Focus
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Jul 29
|
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
|
|
Jul 29
|
Prio And Two Other Stocks That May Be Priced Below Their Estimated Value
|
|
Jun 18
|
Top Value Stocks That Could Be Bargains In June 2024
|
|
Apr 25
|
UCB SA's Dividend Analysis
|
|
Mar 22
|
UCB Convening Notice to the General Meeting of the Shareholders 2024
|
|
Jan 3
|
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
|
|
Dec 2
|
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
|
|
Dec 1
|
UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
|
|
May 24
|
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
|